- Home
- CREX vs NXTC Comparison
CREX vs NXTC Comparison
Compare CREX & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREX
- NXTC
- Stock Information
- Founded
- CREX N/A
- NXTC 2015
- Country
- CREX United States
- NXTC United States
- Employees
- CREX N/A
- NXTC N/A
- Industry
- CREX EDP Services
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- CREX Technology
- NXTC Health Care
- Exchange
- CREX Nasdaq
- NXTC Nasdaq
- Market Cap
- CREX 28.1M
- NXTC 23.0M
- IPO Year
- CREX N/A
- NXTC 2019
- Fundamental
- Price
- CREX $2.55
- NXTC $0.80
- Analyst Decision
- CREX Strong Buy
- NXTC Strong Buy
- Analyst Count
- CREX 2
- NXTC 2
- Target Price
- CREX $8.00
- NXTC $4.00
- AVG Volume (30 Days)
- CREX 49.4K
- NXTC 199.8K
- Earning Date
- CREX 11-13-2024
- NXTC 03-20-2025
- Dividend Yield
- CREX N/A
- NXTC N/A
- EPS Growth
- CREX N/A
- NXTC N/A
- EPS
- CREX 0.07
- NXTC N/A
- Revenue
- CREX $54,300,000.00
- NXTC N/A
- Revenue This Year
- CREX $13.37
- NXTC N/A
- Revenue Next Year
- CREX $17.58
- NXTC N/A
- P/E Ratio
- CREX $35.65
- NXTC N/A
- Revenue Growth
- CREX 31.80
- NXTC N/A
- 52 Week Low
- CREX $2.40
- NXTC $0.76
- 52 Week High
- CREX $5.20
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- CREX 41.33
- NXTC 38.00
- Support Level
- CREX $2.43
- NXTC $0.76
- Resistance Level
- CREX $2.71
- NXTC $0.83
- Average True Range (ATR)
- CREX 0.18
- NXTC 0.06
- MACD
- CREX 0.02
- NXTC 0.01
- Stochastic Oscillator
- CREX 24.59
- NXTC 18.72
About CREX Creative Realities Inc.
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to global retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The Company operates in one reportable segment, marketing technology solutions. The company provides solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.